FilingReader Intelligence

Sun Pharma reports strong growth, specialty sales surge

March 4, 2025 at 07:03 PM UTCBy FilingReader AI

Sun Pharma (BSE: SUNPHARMA) reported strong financial results, with FY24 sales reaching Rs 477.58 Bn, a 10% increase year-over-year. Adjusted net profit rose 16% to Rs 100.71 Bn. The company's specialty business is a key growth driver, accounting for 32% of US revenue. With increased focus on research and development, Sun Pharma invested Rs 31.78 Bn in FY24. The company aims to sustain topline growth by enhancing the specialty product portfolio, expanding in emerging markets, and optimizing operational efficiency. A strong global presence, with operations in over 100 countries, allows the company to make strategic acquisitions, which are critical for sustaining growth and strengthening its position in key therapeutic areas.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Sun Pharmaceutical Industries publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →